Targeting macrophage ASK1 (ASK1 inhibitor Selonsertib), CCR5 (CCR5 antagonist Maraviroc), CCR2 (CCR2/5 due-inhibitor Cenicriviroc), and CSF1 (CSF1R antibody and inhibitor) have been proved to have a good therapeutic effect on acute liver failure. The gene discussed is CCR2; the disease is acute liver failure.